Interleucinas 32 e 38 circulantes em pacientes com infarto agudo do miocárdio submetidos a intervenção coronariana percutânea primária
DOI:
https://doi.org/10.53660/PRW-2381-4337Resumo
A intervenção coronariana percutânea primária (ICPP) é o tratamento padrão-ouro no infarto agudo do miocárdio com supradesnivelamento do segmento ST (IAMCCST). Nesse contexto, as interleucinas (IL) IL-22 e IL-38 atuam na modulação das respostas inflamatórias, sendo potenciais biomarcadores. Objetivos: Comparar os níveis de IL-32 e IL-38 entre pacientes com IAMCSST submetidos a ICPP e controles saudáveis. e analisar os níveis séricos dessas ILs de acordo com a artéria culpada, o tempo porta-balão, o resultado angiográfico final, a extensão da doença arterial coronariana (DAC) e quanto a presença de Diabetes mellitus (DM). Métodos: Foram recrutados 280 participantes (210 casos vs 70 controles). Os níveis séricos das IL-32 e IL-38 foram quantificados por ELISA (Enzyme-Linked Immunosorbent Assay). Realizada a análise estatística pelos testes de Mann-Whitney e exato de Fisher com p significativo < 0,05. Resultados: Não houveram diferenças entre os pacientes vs controles. A IL-32 foi mais elevada nos pacientes com DAC multiarterial vs uniarterial 0,00 (0,00 – 385,03) vs 0,00 (0,00 – 69,20), p = 0,013. Conclusões: A IL-32 pode ser um biomarcador da extensão da DAC.
Downloads
Referências
D, LLOYD-JONES et al. Heart Disease and Stroke Statistics-2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, [s.l.], v. 119, n. 3, p.480-486, 15 dez. 2008. Ovid Technologies (Wolters Kluwer Health). Disponível em: http://dx.doi.org/10.1161/circulationaha.108.191261.
BRASIL. Ministério da saúde. SVS - sistema de informações de mortalidade (SIM). Disponível em: http://www.tabnet.datasus.gov.br. Acesso em: 03 jan. 2024.
MARINHO, Fatima. Prognóstico da Doença Arterial Coronariana em Hospitais úblicos no Brasil: o estudo erico e uso do conhecimento na saúde pública. Arquivos Brasileiros de Cardiologia, [S.L.], v. 117, n. 5, p. 986-987, nov. 2021. Sociedade Brasileira de Cardiologia. Disponível em: http://dx.doi.org/10.36660/abc.20210825.
LIBBY, Peter. Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. New England Journal Of Medicine, [s.l.], v. 368, n. 21, p.2004-2013, 23 maio 2013. New England Journal of Medicine (NEJM/MMS). Disponível em: http://dx.doi.org/10.1056/nejmra1216063.
IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–77.
MEDINA-LEYTE, Diana Jhoseline; ZEPEDA-GARCÍA, Oscar; DOMÍNGUEZ-PÉREZ, Mayra; GONZÁLEZ-GARRIDO, Antonia; VILLARREAL-MOLINA, Teresa; JACOBO-ALBAVERA, Leonor. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: potential biomarkers and promising therapeutical approaches. International Journal Of Molecular Sciences, [S.L.], v. 22, n. 8, p. 3850, 8 abr. 2021. MDPI AG. Disponível em: http://dx.doi.org/10.3390/ijms22083850.
INCALZA, M.A.; D’ORIA, R.; NATALICCHIO, A.; PERRINI, S.; LAVIOLA, L.; GIORGINO, F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul. Pharmacol. 2018, 100, 1–19. [CrossRef].
FRAMPTON, Jennifer; DEVRIES, James T.; WELCH, Terrence D.; GERSH, Bernard J.. Modern Management of ST-Segment Elevation Myocardial Infarction. Current Problems In Cardiology, [S.L.], v. 45, n. 3, p. 100393, mar. 2020. Elsevier BV. Disponível em: http://dx.doi.org/10.1016/j.cpcardiol.2018.08.005
VOGEL, Birgit; CLAESSEN, Bimmer E.; ARNOLD, Suzanne V.; CHAN, Danny; COHEN, David J.; GIANNITSIS, Evangelos; GIBSON, C. Michael; GOTO, Shinya; KATUS, Hugo A.; KERNEIS, Mathieu. ST-segment elevation myocardial infarction. Nature Reviews Disease Primers, [S.L.], v. 5, n. 1, p. 1-20, 6 jun. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41572-019-0090-3
LIBBY, Peter; PASTERKAMP, Gerard; CREA, Filippo; JANG, Ik-Kyung. Reassessing the Mechanisms of Acute Coronary Syndromes. Circulation Research, [S.L.], v. 124, n. 1, p. 150-160, 4 jan. 2019. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1161/circresaha.118.311098.
A BERGMARK, Brian; MATHENGE, Njambi; A MERLINI, Piera; LAWRENCE-WRIGHT, Marilyn B; GIUGLIANO, ROBERT P. Acute coronary syndromes. The Lancet, [S.L.], v. 399, n. 10332, p. 1347-1358, abr. 2022. Elsevier BV. http://dx.doi.org/10.1016/s0140-6736(21)02391-6.
LOH JP, TAN LL, ZHENG H, et al. First medical contact-to-device time and heart failure outcomes among patients undergoing primary percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 2018; 11: e004699.
DE ALBUQUERQUE, R., KOMSI, E., STARSKAIA, I., ULLAH, U., & LAHESMAA, R. (2021). The role of Interleukin-32 in autoimmunity. Scandinavian journal of immunology, 93(2), e13012. https://doi.org/10.1111/sji.13012.
KIM SH, HAN SY, AZAM T, YOON DY, DINARELLO CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22(1):131- 142. S1074-7613(04)00380-2.
BUNET, R., ROY-CARDINAL, M. H., RAMANI, H., CLERET-BUHOT, A., DURAND, M., CHARTRAND-LEFEBVRE, C., ROUTY, J. P., THOMAS, R., TROTTIER, B., ANCUTA, P., HANNA, D. B., LANDAY, A. L., CLOUTIER, G., TREMBLAY, C. L., & EL-FAR, M. (2023). Differential Impact of IL-32 Isoforms on the Functions of Coronary Artery Endothelial Cells: A Potential Link with Arterial Stiffness and Atherosclerosis. Viruses, 15(3), 700. https://doi.org/10.3390/v15030700.
YANG, Z., SHI, L., XUE, Y., ZENG, T., SHI, Y., LIN, Y., & LIU, L. (2019). Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. Clinica chimica acta; international journal of clinical chemistry, 497, 104–109. https://doi.org/10.1016/j.cca.2019.07.019.
YANG Z, SHI L, XUE Y et al (2019) Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. Clin Chim Acta 497:104–109.
CHEN, W., XI, S., KE, Y., & LEI, Y. (2023). The emerging role of IL-38 in diseases: A comprehensive review. Immunity, inflammation and disease, 11(8), e991. https://doi.org/10.1002/iid3.991.
MORA J, SCHLEMMER A, WITTIG I, et al. Interleukin‐38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8(5):426‐438.
SUN X, HOU T, CHEUNG E, et al. Anti‐inflammatory mechanisms of the novel cytokine interleukin‐38 in allergic. Cell Mol Immunol. 2020;17(6):631‐646.
LU, C., ZHOU, F., XIAN, H., SUN, S., YUE, J., ZHANG, Y., ZHAO, Q., LUO, X., & LI, Y. (2023). Serum IL-38 Level Was Associated with Incidence of MACE in the STEMI Patients. International journal of general medicine, 16, 2987–2997. https://doi.org/10.2147/IJGM.S417471
CHESEBRO JH, KNATTERUD G, ROBERTS R, et al. Trombolisys in myocardial infartion (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenousstreptokinase: clinial findings through hospital discharge. Circulation. 1987; 76:142-154.
DAMEN, M. S. M. A., POPA, C. D., NETEA, M. G., DINARELLO, C. A., & Joosten, L. A. B. (2017). Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. Atherosclerosis, 264, 83–91. https://doi.org/10.1016/j.atherosclerosis.2017.07.005
JIN, S., LIU, X., WANG, Y., YU, J., & JIANG, M. (2022). Effects of IL-32 polymorphisms and IL-32 levels on the susceptibility and severity of coronary artery disease. Journal of clinical laboratory analysis, 36(1), e24114. https://doi.org/10.1002/jcla.24114
LI, W., LIU, Y., MUKHTAR, M. M., GONG, R., PAN, Y., RASOOL, S. T., GAO, Y., KANG, L., HAO, Q., PENG, G., CHEN, Y., CHEN, X., WU, J., & ZHU, Y. (2008). Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PloS one, 3(4), e1985. https://doi.org/10.1371/journal.pone.0001985
FAZEL, R; JOSEPH TI; SANKARDAS MA, et al. Comparison of reperfusion strategies for ST-segment-elevation myocardial infarction: a multivariate network meta-analysis. J Am Heart Assoc 2020; 9: e015186.
FADAEI, R., BAGHERI, N., HEIDARIAN, E., NOURI, A., HESARI, Z., MORADI, N., AHMADI, A., & Ahmadi, R. (2020). Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-α and IL-6. Cytokine, 125, 154832. https://doi.org/10.1016/j.cyto.2019.154832
V. CATALAN, J. GOMEZ-AMBROSI, A. RODRIGUEZ, B. RAMIREZ, V. VALENTI, R. MONCADA, M.F. LANDECHO, C. SILVA, J. SALVADOR, G. FRUHBECK, Increased Interleukin-32 levels in obesity promote adipose tissue inflammation and extracellular matrix remodeling:effect of weight loss, Diabetes 65 (12) (2016) 3636–3648.
ZHONG, Y., YU, K., WANG, X., WANG, X., JI, Q., & ZENG, Q. (2015). Elevated Plasma IL-38 Concentrations in Patients with Acute ST-Segment Elevation Myocardial Infarction and Their Dynamics after Reperfusion Treatment. Mediators of inflammation, 2015, 490120. https://doi.org/10.1155/2015/490120.
ZHAO, T., YU, M., LI, M., & LI, Y. (2022). Serum IL-38 levels in patients with type 2 diabetes mellitus. Endokrynologia Polska, 73(6), 988–989. https://doi.org/10.5603/EP.a2022.0089
XU K, SUN J, CHEN S, et al. Hydrodynamic delivery of IL‐38 gene alleviates obesity‐induced inflammation and insulin resistance. Biochem Biophys Res Commun. 2019;508(1):198‐202.
